Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19

Florian Tran*, Danielle M.M. Harris, Alena Scharmacher, Hanna Graßhoff, Kristina Sterner, Susanne Schinke, Nadja Käding, Jens Y. Humrich, Otávio Cabral-Marques, Joana P. Bernardes, Neha Mishra, Thomas Bahmer, Jeanette Franzenburg, Bimba F. Hoyer, Andreas Glück, Martina Guggeis, Alexander Ossysek, Andre Küller, Derk Frank, Christoph LangeJan Rupp, Jan Heyckendorf, Karoline I. Gaede, Howard Amital, Philip Rosenstiel, Yehuda Shoenfeld, Gilad Halpert, Avi Z. Rosenberg, Kai Schulze-Forster, Harald Heidecke, Gabriela Riemekasten, Stefan Schreiber

*Corresponding author for this work
8 Citations (Scopus)
Original languageEnglish
JournalERJ Open Research
Volume8
Issue number4
DOIs
Publication statusPublished - 2022

Funding

We thank M. Rohm, M. Hansen and R. Möhring for perfect technical assistance. This work was supported by COVID-response grants of the state SH, ExC 2167 Precision Medicine in Chronic Inflammation (RTF-VI), the research group miTARGET and the BMBF iTREAT project to P.R, the IMI2 Project 3TR (P.R. and S.S.), EU projects SYSCID (733100 to P.R.). C.L. is supported by the German center for Infection Research (DZIF). The BioMaterialBank Nord is supported by the German Center for Lung Research (DZL), Airway Research Center North (ARCN). The BioMaterialBank Nord is member of popgen 2.0 network (P2N). We are indebted to the patients, their families and the hospital staff for support, without whom this study would not have been possible.

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Coronavirus related work

  • Research on SARS-CoV-2 / COVID-19

Cite this